NJ-IFF
19.8.2022 12:57:15 CEST | Business Wire | Press release
IFF (NYSE:IFF) today announced the opening of its new Nourish Innovation Lab at the company’s Union Beach, New Jersey research and development center. In the state-of-the-art lab, scientists—including flavorists and food designers—will leverage tools, technologies and ingredient expertise to offer customers full product design, driving growth in the global food and beverage markets by fast forwarding innovation.
“This new facility is a testament to how we pioneer innovation and drive speed to market and accessibility to our customers,” said Nicolas Mirzayantz, president of Nourish, IFF. “We will nurture an innovation project from concept to kitchen table, under one roof. Using our scientific knowhow, application excellence and full portfolio of ingredients, we’ll improve the taste and nutrition profiles of next-generation food and beverages. With our new culinary kitchen, we’re enabling technology focused on the consumer-eating experience, taking food development out of the traditional lab setting and into the kitchen.”
Conveniently located in the greater New York City area, the cutting-edge lab will integrate IFF R&D projects with commercial applications desired by consumers, with a special focus on wellness, sustainability and advancing the circular economy. IFF scientists will co-innovate with customers throughout the entire process, allowing for increased customer feedback and faster commercialization.
“Translating leading-edge science into consumer products requires ingenuity and iteration,” said Gregory Yep, IFF executive vice president, chief research and development, global integrated solutions and sustainability officer. “The Nourish Innovation Lab is yet another example of how IFF continues to invest in scientific discovery. At this location and around the world, our best-in-class science bench is foundational to our strategy to bring customers specialized insights, while continuously looking for new challenges and developing new-to-world solutions.”
“At the Nourish Innovation Lab, IFF will service customers using the full portfolio of products from today’s IFF, which includes proteins, maskers, modulators, sweeteners, seasonings, functional ingredients, cultures and enzymes,” said Mauricio Poulsen, vice president of Global Innovation, Creation & Design, Nourish, IFF. “The innovation lab will support both the creation and design needs of all key categories, including snacks, beverages, savory, sweet, dairy, pharma and oral care. The site is the global hub for enabling technologies including a full-scale sensory and consumer insights lab, as well as an analytical lab.”
The Nourish Innovation Lab is one in a series of aggressive investments IFF is making to broaden co-creation capabilities. The 160,000-square-foot Union Beach facility has served as IFF’s premier taste and scent research center for more than half a century, and includes a botanical garden, sensory science wing and pilot manufacturing site. The lab’s proximity to scientists from different backgrounds will allow for further collaboration and out-of-the-box solutions which blend science and creativity.
“Our investment in Union Beach reinforces our commitment to deliver advanced technologies and solutions in lock-step with our customers,” said Adam Janczuk, vice president of global research and development Nourish, IFF. “We’re proud of this accomplishment, which closely follows the openings of our regional innovation centers in Latin America, and the plant-protein focused Culinary Design Center in Brabrand, Denmark. We can’t wait to leverage these new opportunities to drive forward what’s next in food by combining science and creativity.”
Welcome to IFF
At IFF (NYSE: IFF), an industry leader in food, beverage, health, biosciences and scent, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners with customers to bring scents, tastes, experiences, ingredients and solutions for products the world craves. Together, we will do more good for people and planet. Learn more at iff.com , Twitter , Facebook , Instagram , and LinkedIn .
© 2022 by International Flavors & Fragrances Inc. IFF is a Registered Trademark. All Rights Reserved.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220818005759/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Redslim expands into Asia-Pacific to support global brands with data and AI infrastructure12.3.2026 07:00:00 CET | Press release
Redslim, a specialist in end-to-end data management solutions and an Astorg portfolio company, today announced its expansion into the Asia-Pacific region and the appointment of Kyriakos Zannikos as Regional Director, APAC. The move marks an important milestone in Redslim’s global growth strategy and brings the company closer to clients operating in one of the world’s fastest-growing and most data-driven consumer markets. As global consumer brands accelerate digital transformation and AI adoption, many organizations still struggle with fragmented data ecosystems spanning multiple agencies, markets and datasets. These challenges are particularly pronounced in Asia-Pacific, where diverse market structures and rapid growth create complex data environments. Redslim helps organizations transform fragmented market information into valuable data assets, empowering clients to make confident decisions and unlock the full value of their data. By building strong data foundations, Redslim supports
Meiji Seika Pharma Initiates Phase I Clinical Trial in Australia Evaluating ME3241, an Anti-PD-1 Agonist Antibody Discovered Through Collaborative Research With FBRI12.3.2026 07:00:00 CET | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Chuo-ku, Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) announced today that it has initiated a Phase I clinical trial of ME3241 (development code), an anti-PD-1 agonist monoclonal antibody discovered through collaborative research with the Foundation for Biomedical Research and Innovation at Kobe (Headquarters: Kobe, Japan; President: Shuh Narumiya; hereinafter “FBRI”). The Phase I clinical trial is designed as a randomized, placebo-controlled, double-blind study, with the objective of evaluating the safety and tolerability of ME3241 following single and multiple dosing, as well as its pharmacokinetics and pharmacodynamics (ClinicalTrials.gov: NCT07422207). ME3241 was discovered through a collaborative research program led by Program Director Tasuku Honjo, a professor emeritus at Kyoto University. PD-1 is a molecule expressed on activated T cells and other lymphocytes that suppresses immune responses. Through this re
Andersen Consulting styrker sin platform med samarbejdsvirksomheden Ambit Iberia12.3.2026 05:55:00 CET | Pressemeddelelse
Andersen Consulting udvider sine kompetencer inden for teknologi og forretningstransformation gennem en samarbejdsaftale med Ambit Iberia, et konsulentfirma, der specialiserer sig i digitale og regulatoriske løsninger til life science-sektoren. Ambit Iberia, der blev stiftet i 2003, har hovedsæde i Spanien og leverer integrerede løsninger inden for rådgivning, teknologi og rekruttering til medicinal-, bioteknologi- og medtechvirksomheder. Virksomheden hjælper kunder med at opfylde skiftende standarder for kvalitet, compliance og lovgivning gennem ydelser, der spænder over regulatoriske anliggender, dataintegritet, validering af it-systemer og digital transformation. Med mere end 20 års brancheerfaring tilbyder Ambit Iberia også ydelser inden for human capital og executive search, der forbinder organisationer med specialiserede fagfolk og topledertalenter, hvilket øger effektiviteten og fremmer bæredygtig vækst i et stærkt reguleret miljø. "Vores fokus har altid været at levere speciali
EIG’s MidOcean Energy to Acquire Additional Gorgon LNG Interest from JERA; Parties Explore Strategic Alliance12.3.2026 03:14:00 CET | Press release
Transaction increases MidOcean’s equity exposure to premier Australian LNG project Adds incremental uncontracted LNG volumes, enhancing portfolio optimization and marketing flexibility Planning future collaborations, exploring further transactions and opportunities with JERA across other assets globally with the aim of creating a future strategic alliance MidOcean Energy (“MidOcean”), a liquefied natural gas (LNG) company formed and managed by EIG, today announced it has entered into definitive agreements with JERA Co., Inc. (“JERA”) to acquire JERA Gorgon Pty Ltd, which holds JERA’s 0.417% interest in the Gorgon LNG project. MidOcean is an existing participant in the Gorgon LNG project, and this transaction increases MidOcean’s interest in Gorgon to 1.417%. The transaction perimeter also includes JERA’s 0.735% interest in the Ichthys LNG project. Subject to the satisfaction of relevant conditions precedent, the interests in Gorgon and Ichthys will be sold to MidOcean, and then the Ich
DCX Launches Comprehensive ECDU Portfolio – Enterprise-Class Coolant Distribution Units From 600 kW to 2.6 MW11.3.2026 16:34:00 CET | Press release
DCX Liquid Cooling Systems today unveiled its new ECDU (Enterprise Coolant Distribution Unit) platform, a family of three purpose-built CDU models that deliver real cooling capacities from 600 kW to 2.6 MW in industry-standard rack and in-row footprints. The portfolio has been engineered specifically for the accelerating transition to direct-to-chip liquid cooling in high-density enterprise, colocation, cloud, and hyperscale AI environments where thermal stability, uptime, and cost-efficiency are non-negotiable. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260311214891/en/ DCX ECDU, the new generation of Enterprise Coolant Distribution Units dedicated to HPC and AI deployments. The lineup consists of: Enterprise ECDU 1380/2600 V1 - Delivers 1.38–2.6 MW of actual cooling capacity (based on real-world secondary-loop conditions). Single-pump configuration reaches flow rates up to 3,333 liters per minute (lpm). Mission Critica
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom